NBP - NASDAQ
NovaBridge Biosciences
$1.75
-0.57%NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
At a Glance
Live Snapshotnbp
Total Debt
Last Annual Value
438.46K
3-Year CAGR
-77%
5-Year CAGR
-50%
10-Year CAGR
-46%
NovaBridge Biosciences Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 NovaBridge Biosciences NASDAQ:NBP | 438.46K | -51.7% | -52.2% | N/A | |
 Design Therapeutics, Inc. NASDAQ:DSGN | 645.00K | -40.4% | -29.2% | N/A | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 133.74M | 23.0% | 35.7% | N/A | |
 DiaMedica Therapeutics Inc. NASDAQ:DMAC | 240.00K | -15.7% | 35.8% | 1.8% | |
 Altimmune, Inc. NASDAQ:ALT | 35.69M | 276.1% | 87.6% | 43.2% | |
 Annexon, Inc. NASDAQ:ANNX | 26.20M | -5.8% | -5.4% | N/A | |
 Aura Biosciences, Inc. NASDAQ:AURA | 17.38M | -3.9% | 77.9% | N/A | |
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | 3.57M | N/A | N/A | N/A | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | 24.88M | -0.2% | 1.9% | -6.5% |
NovaBridge Biosciences Fair Value Envelope
Related Guides
Continue your NBP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.